Latest Market Impact News

Simble Solutions is on the cusp of revealing initial results from its NanoSensor technology development, targeting major markets including Industrial IoT, defence sensing, and wearable medical devices.

Microba Life Sciences has voluntarily suspended trading of its shares from 5 June 2026, ahead of a material capital raise and an update on its path to break even, expected by 11 June.

Ampol's acquisition of EG Australia has gained ACCC approval, conditional on divesting 41 overlapping fuel sites to Metro Petroleum to preserve competition in 39 local markets.

The ACCC has moved Peter Warren Automotive’s acquisition of Wakeling Automotive’s 30 dealership sites into a Phase 2 review amid concerns it could dominate Sydney’s Macarthur region new car market, controlling 25 of 33 dealerships locally.

Spenda Limited (ASX: SPX) has voluntarily suspended trading of its shares from 2 June 2026 to manage disclosure around its institutional accelerated renounceable entitlement offer (AREO). The suspension is expected to last until 10 June or until the AREO results are announced.

Nova Minerals shareholders and Nasdaq warrantholders overwhelmingly approved schemes to restructure the company under a new US holding entity, pending final court approval.

Arafura Rare Earths has successfully completed the first tranche of its A$350 million placement, issuing 675.1 million shares and raising approximately A$175.5 million before costs. The second tranche awaits shareholder approval.

Almonty Industries is set to join the prestigious Russell 1000 and 3000 indexes in June 2026, marking a significant milestone that highlights its growth and operational progress amid rising tungsten demand.

Delorean Corporation has closed its Share Purchase Plan, raising $750,000 through the issue of over 8.3 million shares at $0.09 each, supplementing earlier strategic funding from LMS Energy.

Vectus Biosystems has secured $791,000 through a placement to accelerate its lead fibrosis drug VB0004's Phase IB clinical trial and advance other drug candidates.

Vmoto Limited disclosed it held only one formal board meeting in FY25, relying heavily on circular resolutions, and outlined plans to increase meeting frequency in 2026. The company clarified its trade insurance arrangements and affirmed director independence amid ASX queries.

Argenica Therapeutics has passed a critical FDA genotoxicity test for its stroke drug ARG-007, advancing its IND application and edging closer to Phase 2b clinical trials in the US and Australia.